Audio long-read: Rise of the robo-writers
In 2020, the artificial intelligence (AI) GPT-3 wowed the world with its ability to write fluent streams of text. Trained on billions of words from books, articles and websites, GPT-3 was the latest in a series of ‘large language model’ AIs that are used by companies around the world to improve search results, answer questions, or propose computer code.However, these large language model are not without their issues. Their training is based on the statistical relationships between the words and phrases, which can lead to them generating toxic or dangerous outputs.Preventing responses like these is a huge challenge for ...
Source: Nature Podcast - April 6, 2021 Category: Science Authors: Springer Nature Limited Source Type: podcasts
Audio long-read: Rise of the robo-writers
In 2020, the artificial intelligence (AI) GPT-3 wowed the world with its ability to write fluent streams of text. Trained on billions of words from books, articles and websites, GPT-3 was the latest in a series of ‘large language model’ AIs that are used by companies around the world to improve search results, answer questions, or propose computer code.However, these large language model are not without their issues. Their training is based on the statistical relationships between the words and phrases, which can lead to them generating toxic or dangerous outputs.Preventing responses like these is a huge challenge for ...
Source: Nature Podcast - April 6, 2021 Category: Science Authors: Springer Nature Limited Source Type: podcasts
Coronapod: How to define rare COVID vaccine side effects
From a sore arm to anaphylaxis, a wide range of adverse events have been reported after people have received a COVID-19 vaccine. And yet it is unclear how many of these events are actually caused by the vaccine. In the vast majority of cases, reactions are mild and can be explained by the body's own immune response. But monitoring systems designed to track adverse events are catching much rarer but more serious events. Now scientists need to work out if they are causally liked to the vaccine, or are just statistical anomalies - and that is not an easy task.News: Why is it so hard to investigate the rare side effects o...
Source: Nature Podcast - April 2, 2021 Category: Science Authors: Springer Nature Limited Source Type: podcasts
Coronapod: How to define rare COVID vaccine side effects
From a sore arm to anaphylaxis, a wide range of adverse events have been reported after people have received a COVID-19 vaccine. And yet it is unclear how many of these events are actually caused by the vaccine. In the vast majority of cases, reactions are mild and can be explained by the body's own immune response. But monitoring systems designed to track adverse events are catching much rarer but more serious events. Now scientists need to work out if they are causally liked to the vaccine, or are just statistical anomalies - and that is not an easy task.News: Why is it so hard to investigate the rare side effects o...
Source: Nature Podcast - April 2, 2021 Category: Science Authors: Springer Nature Limited Source Type: podcasts
TWiV 708: Alpaca llama full of nanobodies
The TWiVy team deconstructs CoronaVac, the inactivated SARS-CoV-2 vaccine produced by Sinovac Biotech, and production of multivalent camelid nanobodies that block infection with the virus and suppress selection of neturalization-resistant variants. Hosts: Vincent Racaniello, Dickson Despommier, Alan Dove, Rich Condit, and Brianne Barker Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode David Kessler to head Operation Warp Speed (NY Times) Phase 1/2 results of Sinovac inactivated vaccine (Lancet) beta-propiolactone (Wikipedia) Multivalent anti-SARS-CoV-2 nanobodie...
Source: This Week in Virology - MP3 Edition - January 17, 2021 Category: Virology Authors: Vincent Racaniello Source Type: podcasts
TWiV 697: The sky is NOT falling
TWiV reviews the latest data on the UK variant of SARS-CoV-2, including some properties of the variant and why it is being closely studied, development of liver cancer in a participant in a adenovirus-associated virus gene therapy trial, and answers to listener questions. Hosts: Vincent Racaniello, Rich Condit, Kathy Spindler, and Brianne Barker Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode BSL-3 Assistant Manager position 3:39 NERVTAG meeting minutes (pdf) NERVTAG Preliminary genomic characterization of UK variant (virological.org) PHE investigation of UK var...
Source: This Week in Virology - MP3 Edition - December 24, 2020 Category: Virology Authors: Vincent Racaniello Source Type: podcasts
Talk evidence covid-19 update - uncertainty in treatment, uncertainty in prevention
Uncertainty abounds - even as we get better data on treatments, with the big RCTs beginning to report, and new trials on masks, the evidence remains uncertain, in both the statistical realm (confidence intervals crossing 0) and in what to do in the face of that continuing lack of clear effect.
As always Helen Macdonald and Duncan Jarvies are looking at the evidence, and this week are joined by John Brodersen, professor of general practice at the University of Copenhagen.
Helen talks to Bram Rochwerg, methodology lead on the WHO treatment guidelines for covid, about why their latest rev iew has stopped recommending remde...
Source: The BMJ Podcast - November 21, 2020 Category: General Medicine Authors: BMJ talk medicine Source Type: podcasts
Talk evidence covid-19 update - uncertainty in treatment, uncertainty in prevention
Uncertainty abounds - even as we get better data on treatments, with the big RCTs beginning to report, and new trials on masks, the evidence remains uncertain, in both the statistical realm (confidence intervals crossing 0) and in what to do in the face of that continuing lack of clear effect.
As always Helen Macdonald and Duncan Jarvies are looking at the evidence, and this week are joined by John Brodersen, professor of general practice at the University of Copenhagen.
Helen talks to Bram Rochwerg, methodology lead on the WHO treatment guidelines for covid, about why their latest review has stopped recommending remdesi...
Source: The BMJ Podcast - November 21, 2020 Category: General Medicine Authors: BMJ Group Source Type: podcasts
When Should Physicians Act on Non –Statistically Significant Results From Clinical Trials?
Interview with Paul J. Young, PhD, author of When Should Clinicians Act on Non–Statistically Significant Results From Clinical Trials? (Source: JAMA Author Interviews)
Source: JAMA Author Interviews - May 8, 2020 Category: General Medicine Authors: JAMA Network Source Type: podcasts
Talk Evidence covid-19 update - hydroxy/chloroquinine, prognostic models and facemaskss
For the next few months Talk Evidence is going to focus on the new corona virus pandemic.
There is an enormous amount of uncertainty about the disease, what the symptoms are, fatality rate, treatment options, things we shouldn't be doing.
We're going to try to get away from the headlines and talk about what we need to know - to hopefully give you some insight into these issues.
This week:
(2.24) - Hydroxychloroquinine/chloroquinine - Robin Ferner, honorary professor of clinical pharmacology at the University of Birmingham explains why is it a potential therapeutic for covid-19, and why is it being hyped.
(12.45) - W...
Source: The BMJ Podcast - April 13, 2020 Category: General Medicine Authors: BMJ talk medicine Source Type: podcasts
Talk Evidence covid-19 update - hydroxy/chloroquinine, prognostic models and facemaskss
For the next few months Talk Evidence is going to focus on the new corona virus pandemic.
There is an enormous amount of uncertainty about the disease, what the symptoms are, fatality rate, treatment options, things we shouldn't be doing.
We're going to try to get away from the headlines and talk about what we need to know - to hopefully give you some insight into these issues.
This week:
(2.24) - Hydroxychloroquinine/chloroquinine - Robin Ferner, honorary professor of clinical pharmacology at the University of Birmingham explains why is it a potential therapeutic for covid-19, and why is it being hyped.
(12.45) - W...
Source: The BMJ Podcast - April 13, 2020 Category: General Medicine Authors: BMJ Group Source Type: podcasts
Communication Strategies for Sharing Prognostic Information With Patients: Beyond Survival Statistics
Interview with Joanna Paladino, MD, author of Communication Strategies for Sharing Prognostic Information With Patients: Beyond Survival Statistics (Source: JAMA Author Interviews)
Source: JAMA Author Interviews - August 15, 2019 Category: General Medicine Authors: JAMA Network Source Type: podcasts
BRCA Mutations and Pancreatic Cancer
Vincent Chung MD, Associate Clinical Professor and Medical Oncologist at City of Hope shares statistics and data on strategies that are emerging concerning BRCA mutations and pancreatic cancer.
Author: obr
Added: 06/25/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 25, 2019 Category: Cancer & Oncology Source Type: podcasts
